Cheaper avastin copycat tested in healthy volunteers

NCT ID NCT03390673

Completed Knowledge-focused Sponsor: Prestige Biopharma Limited Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 30, 2026 · Updated 4 times

Summary

This study tested a new biosimilar drug called HD204 against the original Avastin in 119 healthy men. The goal was to see if the body processes both drugs the same way. Participants received a single dose, and researchers measured drug levels and safety. The trial is complete, but it only looked at healthy volunteers, not patients with disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Bevacizumab (HD204, a biosimilar version of Avastin)
What this could lead to: If successful, this could show that HD204 works similarly to Avastin, potentially offering a more affordable treatment option for conditions like cancer.
What could go wrong: This is an early-phase trial in healthy volunteers, not patients. It only checks how the drug moves through the body, not if it treats disease. Results may not predict real-world effectiveness or safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS

Contacts and locations

Locations

Auckland Clinical Studies

Auckland, 1010, New Zealand
Christchurch Clinical Studies Trust Ltd

Christchurch, 8011, New Zealand

More trials for these conditions

Other studies related to the condition(s) this trial covers.